Specifically, IL-6 individually associates with an unfavorable prognosis in LUAD patients between the age of 46 and 65 or tumors at stage II; female LUAD patients and those with tumors diagnosed at stage I or without KRAS mutation suffer a higher risk of tumor occurrence if their tumors highly express CXCL8; for male LUAD patients, this is also the case if their tumors highly express CSF3. This evidence concerns the gene KRAS and neoplasm.